SVCP
MRNA icon

Silicon Valley Capital Partners’s Moderna MRNA Stock Holding History

Silicon Valley Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58
Closed -$6.89K – 318
2024
Q2 		$6.89K Hold
58
– – ﹤0.01% 258
2024
Q1 		$6.18K Buy
+58
New +$5.85K ﹤0.01% 260

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Silicon Valley Capital Partners's MRNA Position: Q3 2024 in Review

Silicon Valley Capital Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 58 shares — an estimated $6.89K sold.

Silicon Valley Capital Partners first reported a position in MRNA in Q1 2024 and held it in 2 quarters. The position peaked at $6.89K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Silicon Valley Capital Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Silicon Valley Capital Partners sold 58 Moderna shares in Q3 2024, an estimated $6.89K.
  • Silicon Valley Capital Partners first reported a position in Moderna in Q1 2024 and held it in 2 quarters.
  • Silicon Valley Capital Partners's Moderna position peaked at $6.89K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Silicon Valley Capital Partners's 13F filing for Q3 2024, filed 30 Oct 2024.